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Objectives: The primary objective of this systemic review and meta-analysis was to
investigate the risk of developing composite outcome of all cancers, regardless of the type
of cancer among men with infertility diagnosis compared to fertile counterparts. The
secondary objective was to compare the pooled risk of developing individual specific
cancers between two groups.
Methods: A systematic literature search was performed on the databases of PubMed
(including Medline), Scopus, and Web of Science to retrieve observational studies
published in English language from 01.01.1990 to 28. 02. 2021. They assessed cancer
events in males with an infertility diagnosis compared to controls without infertility. The
outcomes of interest were a composite outcome of cancers including all known cancer
types, and also specific individual cancers. The fixed/random effects model was used to
analyze heterogeneous and non-heterogeneous results. Publication bias was assessed
using the Harbord test, Egger test, Begg test, and funnel plot. The pooled odds ratio of
cancers was calculated using the DerSimonian and Laird, and inverse variance methods.
Studies’ quality and risk of bias were assessed using structured standard tools.
Results: We included eight cohort studies involving 168,327 men with the diagnosis of
infertility and 2,252,806 men without it. The total number of composite outcome of
cancers as well as individual cancers including prostate, testicular and melanoma were
1551, 324, 183 and 121 in the infertile men and 12164, 3875, 849, and 450 in the fertile
men, respectively. The pooled OR of the composite outcome of cancers, regardless of the
type of cancer, in men with infertility was 1.4 folds higher than those without infertility
(pooled OR = 1.43, 95% confidence interval [CI]: 1.25-1.64). Meta-analysis of individual
cancers including prostate, testicular and melanoma between two groups was carried
out. The pooled ORs of testicular and prostate cancers in men with the diagnosis of
infertility were significantly higher than controls without infertility (pooled OR = 1.91, 95%
CI: 1.52-2.42 and pooled OR = 1.48, 95% CI: 1.05-2.08, respectively). Additionally, the
pooled OR of melanoma in men with infertility was 1.3 folds higher than those without
infertility (pooled OR = 1.31, 95% CI: 1.06-1.62).October 2021 | Volume 11 | Article 6967021
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Frontiers in Oncology | www.frontiersin.orgConclusion: A greater risk of cancers in men with male infertility was found suggesting
that the history of male infertility might be an important risk factor for developing cancers in
later life. Further well-designed long-term population-based prospective studies,
considering all known cancers and their accompanying risk factors should be
conducted to support our findings.Keywords: melanoma, prostate cancer, risk, testicular cancer, male infertilityINTRODUCTION
Infertility is defined as failure to achieve a clinical pregnancy
after 12 months or more of regular unprotected sexual
intercourse (1). Male infertility is solely responsible for 10-30%
of infertility cases and contribute to 50% of overall infertility
cases (2, 3). Although male infertility is not a reportable disease,
the manifestations of male infertility can signify a future health
concern (4–6). The growing body of literature suggests that male
infertility can be a potential marker of contemporary or future
medical diseases including cardiovascular metabolic and
autoimmune disorders as well as mortality. However, exact
mechanisms behind these associations remain elusive (6–10).
It has been reported that both genetics and environmental
factors can play an important role in developing cancer among
males suffering from infertility (9, 11). It is believed that male
infertility, per se, may play as a risk factor for the development of
genitourinary cancers in men (12). However, studies on cancers
amongmenwith infertilityhave reported controversial results.Mao
et al., in a systematic reviewandmeta-analysis of 11 studies reported
that being childless was associated with a lower risk of prostate
cancer (13). Incontrast, ina recentlypublishedmeta-analysisbyDel
Giudice et al. (12) on six population-based cohort studies, male
infertility was associated with a subsequent risk of male-specific
malignancies including testicular cancer and prostate cancer.
Given the lack of conclusive evidence regarding the risk of
overall as well as individual cancers, the primary aim of our
systemic review and meta-analysis was to investigate the risk of
developing composite outcome of all cancers, regardless of the
type of cancer among men with infertility compared to fertile
men. The secondary objective was to compare the pooled risk of
developing individual specific cancers between men with
infertility compared to fertile men.MATERIAL AND METHODS
This systematic review and meta-analysis was performed by the
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) (14), to achieve the following objectives:
• to study the pooled risk of developing composite outcome of
all cancers, regardless of the type of cancer among men with
the diagnosis of infertility compared to fertile men;
• to compare the pooled risk of developing individual specific
cancers between men with the diagnosis of infertility and
fertile men.2
The review question was framed using the PICO (population,
intervention/Index, control, and outcomes) statement as follows: P:
men with the diagnosis of male infertility; I: risk of developing
cancer; C: men without male infertility; O: overall and individual
cancer. Study protocol was developed before the study and was used
as the guideline to conduct this research (Supplementary Table 1).
Eligibility Criteria
All types of observational cohort studies including prospective,
retrospective, and registered-based data studies assessing the risk
of subsequent cancer development in men with the diagnosis of
male infertility were eligible to be included in this systematic
review and meta-analysis.
In addition, studies should have subjects without infertility as
the control group; clearly define male infertility and cancers;
report the number, prevalence, and risk of cancer in the groups.
The presence of preexisting cancer before male infertility
diagnosis, and also the lack of any differentiation between male
and female infertility led to exclusion. Also, gray literature and
non-original studies including reviews, commentaries, editorials,
letters, meeting abstracts, case reports, conference proceedings,
governmental or organizational reports, dissertations, theses,
unpublished data and presentations that did not provide
accurate and clear data on research variables were excluded.
Search Strategy
A comprehensive literature search was performed on the
databases of PubMed (including Medline), Scopus, and Web of
Science to retrieve observational studies published in English
language from 01.01.1990 to 28.02.2021. They should have
investigated the risk of the development of cancer in males
with the diagnosis of infertility. Further, a manual search in
the references list of selected studies and other relevant reviews
was carried out to maximize the identification of eligible studies.
The following keywords, alone or in combination, were used
during the search process: (male infertility OR male sterility OR
male sub-fertility OR azoospermia OR oligospermia OR semen
quality OR fertility impairment) AND (cancer OR neoplasms
OR neoplasia OR tumors OR carcino* OR onco* OR benign OR
hyperplasia OR malignancies OR malignancy OR carcinoma)
(Supplementary Table 2).
Study Selection and Data Extraction
The titles, abstracts, and full texts of selected studies were
screened independently by two review authors based on the
eligibility criteria and the following data was extracted from
eligible studies: first author’s name; journal title; publication year;October 2021 | Volume 11 | Article 696702
Behboudi-Gandevani et al. Male Infertility and Cancer Riskcountry; study design; sample size; population characteristics
including age and body mass index (BMI); definition of
infertility; follow-up period; quality assessment; outcome
measurements in terms of the number and prevalence of
cancer. Any disagreement in the selection of studies was
resolved through holding discussions between the authors and
also seeking comments from the third review author. The data
extraction process was double-checked to ensure the accuracy of
data collection before the meta-analysis and prevent bias in data
extraction and data entry.
Outcome Measures
Primary outcome of interest was the pooled risk of developing
composite outcome of all cancers, regardless of the type of cancer
among men with the diagnosis of infertility. Secondary outcome
was the pooled risk of developing individual specific cancers
among men with the diagnosis of infertility. Male infertility was
defined as men reporting the experience of infertility with the
duration of more than one year (15).
Quality Appraisal
Quality of the included studies was critically appraised in terms of
the methodological structure and presentation of results. Two
authors were made blind to the study’s author, country, and the
journal’s title to evaluate the quality of each study independently.
The quality of observational studies was assessed using the
modification of the Newcastle–Ottawa Quality Assessment Scale
for Non-Randomized Studies (NRS) (16). This scale contains 8
items within 3 main domains of selection, comparability and
outcomes with the maximum and minimum scores of 9 and zero,
respectively. Studies with scores above 6 were considered high
quality, 4–6 moderate quality, and less than 4 low quality.
The Risk Of Bias in Non-randomized Studies (ROBINS) tool
in non-randomized studies of interventions and observational
studies was used to assess risk of bias (17) as the Cochrane
Collaboration has recommended (18). Seven domains of (i)
selection of exposed and non-exposed cohort, (ii) assessment
of exposure, (iii) presence of the outcome of interest at the
beginning of the study, (iv) control of prognostic variables, (v)
assessment of the presence or absence of prognostic factors, (vi)
assessment of outcome, and (vii) adequacy of follow-up were
used for appraisal. The review authors judged the quality of each
study and classified it into serious, critical, moderate, and low
risk of bias and no information.
Statistical Analysis
Meta-analysis was performed to evaluate the pooled OR (95%
CI) of the outcomes of interest including individual cancers and
composite of all cancers. Heterogeneity was evaluated using the
I-squared (I2) statistics and values above 50% were interpreted as
heterogeneity. Given the heterogeneous results of the included
studies, the pooled effect was calculated using the random effect
model. Publication bias was assessed through the visual
inspection of funnel plot, Harbord test, Egger test, and Begg
test. When the funnel plot is symmetrical and the p values of
Harbor test, Begg test, and Egger test are >0.05, no significant
publication bias exists in the meta-analysis. Pooled OR (95% CI)Frontiers in Oncology | www.frontiersin.org 3was estimated using the DerSimonian and Laird, and inverse
variance methods. Forest plots were drawn to show the
estimation of pooled OR (95% CI) in the included studies.
Sensitivity analysis was run to investigate the influence of each
individual study on the estimation of overall meta-analysis
summary. The graph of the results of an influence analysis in
which the meta-analysis was re-estimated, omitting each study in
turn, was drawn. Significant level was considered p <0.05 and all
statistical analyses were performed using the STATA software
(version 14; STATA, INC., College Station, TX, USA).RESULTS
Search Results, Study Selection, Study
Characteristics, and Quality Assessment
Figure 1 illustrates the flow diagram of the search strategy and
study selection. In the initial search, 846 studies were retrieved. Of
which, 529 articles were duplicate appearing in multiple databases,
which were excluded. During abstract reading, 253 studies were
excluded because they were irrelevant, did not examine male
infertility, or contained in-vivo examinations. The full-text of 64
remaining studies were assessed and 56 studies that did not meet
the inclusion criteria were also excluded. The remaining studies
(n=8) were selected for the final research analyses consisting of
168,327 men with the diagnosis of infertility and 2,252,806 men
without it. With regard to their methodologies, 7 were retrospective
studies (19–25) and one was prospective cohort study (11). A total
of 5 studies were conducted in the USA (19–23), two in Sweden
(11, 25) and one in Denmark (24). Table 1 shows a summary of the
included studies.
Four studies assessed the riskof testicular cancer (20–22, 24),five
evaluated prostate cancer (11, 20, 21, 23, 25), two examined
melanoma (20, 21). In addition, three studies reported the other
types of oncologic outcomes of kidney, upper aerodigestive,
stomach, colon and rectum, liver and gallbladder, pancreas,
urinary bladder, breast and lung, esophagus, leukemia, Hodgkin
lymphoma, non-Hodgkin lymphoma, thyroid, nervous system,
peritoneum, and rest of cancers (20, 21, 24) and one study
reported the risk of all cancers in both men with and without
infertility (19). The quality assessment of the included studies has
been presented in Supplementary Table 3. All studies were
classified as high quality.
Meta-Analysis of Outcomes
Table 2 shows the pooled OR of single and composite cancers,
estimation of heterogeneity, and assessment of publication bias
in both groups.
In term of composite outcome of cancers, a total of 8 studies
involving 1,585,940 men with infertility and 15,862,783 men
without infertility were entered into the meta-analysis. The
pooled OR of cancers, regardless of type of cancer, among men
with the diagnosis of infertility was 1.4 folds higher than men
without it (PooledOR=1.46, 95%CI: 1.20-1.78) (Figure2A).Meta-
analysis of individual cancers was conducted and compared for
prostate, testicular and melanoma between the groups. A total of 4
studies including 130,242 men with male infertility and 1,095,820October 2021 | Volume 11 | Article 696702
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The risk of testicular cancer in men with male infertility was 1.9
foldshigher thanmenwithout infertility (PooledOR=1.91,95%CI:
1.52-2.42) (Figure 2B).
Regarding prostate cancer, a total of 5 studies involving 138,699
men with infertility and 1,951,019 men without infertility were
included in the meta-analysis. The pooled risk of prostate cancerFrontiers in Oncology | www.frontiersin.org 5in men with infertility was 1.4 folds higher than men without
infertility (Pooled OR = 1.48, 95% CI: 1.05-2.08) (Figure 2B). A
total of two studies including 96,516 men with infertility and
781,263 men without infertility were entered into the meta-
analysis. It was demonstrated that the pooled OR of melanoma
in men with infertility was 1.3 folds higher than those without
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impaired semen analysis for the diagnosis of male infertility. The
risk of composite outcome of cancers increased in men with
impaired semen analysis compared to controls (Pooled OR =
1.42, 95% CI: 1.18-1.71) (Supplementary Figure 2).
Heterogeneity and Sensitivity Analysis
No statistically significant heterogeneity was found in the studies
with regard to the assessment of testicular cancer and melanoma
(all I2 < 50%, P > 0.05), whereas heterogeneity was observed
among the studies with regard to the analysis of the composite
outcome of all cancers and prostate cancer (all I2 > 50%, P < 0.01)
(Table 2). However, sensitivity analysis showed that no single
study essentially changed the pooled OR of all outcomes
(Figures 3A–D).
Publication Bias and Risk of Bias
According to the results of publication bias tests, no substantial
publication bias for meta-analysis was observed (Table 2), which
also was confirmed by the symmetric funnel plot (Figures 4A, B).
Additionally, the included studies mostly were judged as having a
low risk of bias for the evaluated domains. All studies had low or
moderate of bias for all domains of selection of exposed and non-
exposed cohorts, assessment of exposure, presence of the outcome
of interest at the beginning of the study, outcome assessment,
assessment of the presence or absence of prognostic factors, and
adequacy of follow up of cohorts. However, approximately, 10%
had a serious risk of bias in controlling prognostic variables
(Supplementary Figures 1A, B).DISCUSSION
Despite the insufficient number of studies for the precise
comparison of the different types of cancers in males with the
diagnosis of infertility, the present systematic review and meta-
analysis based on available evidence revealed that the risk of
cancer regardless of the type of cancer and also the risk ofFrontiers in Oncology | www.frontiersin.org 6individual cancers of testis, melanoma, and prostate increased in
men with the diagnosis of infertility.
Male infertility is a heterogeneous, complex, and mostly
multifactorial problem. The exact etiology of male infertility is
unknown, with half of cases classified as idiopathic or
unexplained (26). Similarly, the association between male
infertility and the occurrence of cancer has been poorly
understood. However, it has been hypothesized that a complex
interaction between genetics and epigenetics, developmental, and
lifestyle or environmental factors can put men with infertility at
the risk of developing cancer in the future (9, 11). In this respect,
at least 1500 genes are known that contribute to spermatogenesis
and any defect in these genes may also potentially lead to the
development of infertility, male genitourinary, and cancer in
other organs (9, 27). Nagirnaja et al. stated that disturbances in
cell survival, cell fate, and genome maintenance might be a
shared biological process in both male infertility and cancer.
Moreover, there were at least 25 tumor-suppressor genes or
oncogenes with a potentially pleomorphic effect that contributed
to both male infertility and the development of a malignancy
(28). Although clear evidence is available in mice, more studies
are needed to explain related associations in humans. In
addition, the environmental toxin exposure, and also prenatal
exposure to commonly used chemicals, e.g. phthalates, may
increase the risk of both infertility and neoplasm in men (29).
Additionally, it has been reported that the fear of infertility
and its consequences may influence help-seeking behaviors in
men, which may trigger diseases in later life (30). The experience
of infertility may negatively impact on personal health behaviors
(31) and in some contexts, it may hinder taking further actions to
prevent health-related problems or seek appropriate treatments
(29). It has been hypothesized that unhealthy behaviors may
predispose infertile patients to cancer. However, this hypothesis
could not be tested in our study and should be considered in
future studies. Nevertheless, early educational programs on
men’s health as inexpensive prevention strategies in the
community should be used to inform them of related health
issues and how to seek appropriate treatments (32).TABLE 2 | Results of heterogeneity estimation and publication bias assessment, and meta-analysis for the risk of cancer among men with infertility compared to men
without infertility.
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Behboudi-Gandevani et al. Male Infertility and Cancer RiskPrior studies have focused on the relationship between the
infertility status and male-specific malignancies. Mao et al.
conducted a systemic review and meta-analysis on the
association between the fatherhood status and the risk of
prostate cancer, and found that the risk of prostate cancer
were lower among childless men (OR = 0.91, 95% CI: 0.87–
0.96) (13). However, the results of this study should be
interpreted with caution because heterogeneity in the
definition of infertility and presence of selection bias might
have distorted pooled estimates. In addition, half of the
included studies had the case-control design, which could be
affected by selection bias and recall bias. Another meta-analysis
by Del Giudice et al. (12) examined the correlation betweenFrontiers in Oncology | www.frontiersin.org 7impaired male fertility and the risk of developing testicular and
prostate cancers in cohort studies. They reported that male
infertility was significantly associated with the subsequent risk
of testicular cancer (RR = 1.68, 95% CI: 1.17-2.4) and prostate
cancer (RR = 2.03, 95% CI: 1.66-2.48) (12). Although narrow
inclusion criteria for this study led to the adoption of a small
number of studies to this meta-analysis, its findings were in
agreement with the finding of our meta-analysis. The findings of
our meta-analysis comprehensively adds new knowledge to the
body of international literature and also helps with the provision
of an updated evidence on this important topic.
Our study have some limitations that should be considered in
the interpretation of data. In our review, a considerableA
B
FIGURE 2 | Forest plot of pooled odds ratio for (A) composite outcome of all cancers; (B) individual cancers of testicular, prostate and melanoma. (A) Forest plot
of the pooled odds ratio for the composite outcome of all cancers. (B) Forest plot of pooled odds ratio for testicular cancer, prostate cancer and melanoma.October 2021 | Volume 11 | Article 696702
nce of each individual study on the overall meta-analysis
hown. They provide the visual results, naming the omitted study
een shown as the solid vertical lines. For interpretation, an







































FIGURE 3 | Plots of sensitivity analysis results (A) all cancers (B) testicular cancer (C) melanoma (D) prostate cancer. These graphs show the influe
summary estimate. Accordingly, the results of an influence analysis in which the meta-analysis is re-estimated omitting each study in turn has been s
on the left margin and omitted meta-analytic summary statistics as horizontal confidence intervals on the right side. The full, combined results have b
individual study is suspected of having an excessive influence if the point estimate of its omitted analysis lies outside the confidence interval of the co
outcome of cancers. (B) Sensitivity analysis plot for testicular cancer. (C) Sensitivity analysis plot for melanoma. (D) Sensitivity analysis plot for prosta
Behboudi-Gandevani et al. Male Infertility and Cancer Riskheterogeneity between the studies that assessed the risk of
prostate cancer was observed. Different criteria for the
screening and recruitment of infertile men in the included
studies, lack of uniform data regarding risk stratification such
as the grade and stage of cancers, and absence of risk factors such
as race/ethnicity, socio-economic and demographics may have
led to the heterogeneity. Therefore, definitive conclusions should
be taken cautiously. Also, the included studies had large sample
sizes in case and control groups, but the number of studies
assessing the occurrence of cancer in men with infertility wasFrontiers in Oncology | www.frontiersin.org 9limited and hindered us to run various subgroup analyses for the
different types of cancers, stages of cancer, and the degree of male
infertility impairment. Moreover, various confounders for the
development of cancer such as lifestyle factors (33) could not be
accounted for in this meta-analysis due to the lack of sufficient
data about them in the included studies. Information about
cancer in the included studies was extracted from databases
that might have caused bias in our results. There is the
possibility of duplicate populations between the included
studies conducted in the USA, since some of them usedA
B
FIGURE 4 | Funnel plot for the visual assessment of publication bias of the outcome of studies; (A) composite outcome of all cancers (B) testicular cancer, melanoma,
and prostate cancer. (A) Composite outcome of cancers. (B) Testicular cancer, melanoma, and prostate cancer.October 2021 | Volume 11 | Article 696702
Behboudi-Gandevani et al. Male Infertility and Cancer Riskdatabases that covered the same population. Gray literature could
be the important source of available knowledge, which were
excluded from our literature search due to the lack of peer
review process and methodological descriptions and details,
which made it difficult to evaluate their quality.CONCLUSION
This systematic review and meta-analysis demonstrated an
increased risk of composite outcome of cancers as well as
melanoma, testicular and prostate cancers in men with the
diagnosis of male infertility. Well-designed long-term prospective
studies, considering all known cancers and their accompanying risk
factors should be conducted to support our findings.DATA AVAILABILITY STATEMENT
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